The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on Clinical and Molecular Predictive Factors

被引:15
|
作者
Krawczyk, Pawel [1 ]
Kowalski, Dariusz M. [3 ,4 ]
Wojas-Krawczyk, Kamila [1 ]
Mlak, Radoslaw [1 ]
Jaskiewicz, Piotr [3 ,4 ]
Kucharczyk, Tomasz [1 ,5 ]
Winiarczyk, Kinga [3 ,4 ]
Krzakowski, Maciej [3 ,4 ]
Milanowski, Janusz [1 ,2 ]
机构
[1] Med Univ Lublin, Dept Pneumonol Oncol & Allergol, Lublin, Poland
[2] Inst Agr Med Lublin, Lublin, Poland
[3] Warsaw Med Univ, Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland
[4] Warsaw Med Univ, Inst Oncol, Warsaw, Poland
[5] Warsaw Med Univ, Postgrad Sch Mol Med, Warsaw, Poland
关键词
Docetaxel; Epidermal growth factor receptor; Erlotinib; Non-small cell cancer; Predictive factors; Second-line therapy; CELL LUNG-CANCER; FACTOR RECEPTOR GENE; III BETA-TUBULIN; ECONOMIC-ANALYSIS; RANDOMIZED-TRIAL; SUPPORTIVE CARE; GEFITINIB; CHEMOTHERAPY; MUTATIONS; PACLITAXEL;
D O I
10.1159/000336143
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: We evaluated the effectiveness of docetaxel or erlotinib in second-line treatment of non-small cell lung cancer (NSCLC) and focused on the impact of predictive factors on the outcome of therapy. Methods: 204 patients with progressive disease after platinum-based therapy were enrolled: 102 received an infusion of 75 mg/m(2) of docetaxel and 102 received 150 mg of erlotinib orally. Results: Response rate (RR) was 6.9 and 8.8% for docetaxel and erlotinib, respectively. Progression-free survival (PFS) was 1.2 months for docetaxel and 1.6 months for erlotinib (hazard ratio, HR = 1.2, p = 0.17). Overall survival was 5.5 versus 7 months for docetaxel and erlotinib, respectively (HR = 1.35, p = 0.06). Using Cox regression, we found clinical factors (performance status and weight loss) with predictive values for RR and PFS in second-line-treated patients. Prior radiotherapy, smoking status and EGFR mutation might help to predict outcome of erlotinib treatment and beta III-tubulin mRNA expression that of docetaxel, but histopathological diagnosis did not have any predictive value. Conclusions: Erlotinib and docetaxel show similar efficacy in the treatment of NSCLC. The application of predictive factors may facilitate qualification for second-line treatment with both drugs. Copyright (C) 2012 S. Karger AG, Basel
引用
收藏
页码:60 / 69
页数:10
相关论文
共 50 条
  • [31] A clinical study of docetaxel with or without 5'DFUR as a second-line chemotherapy for advanced gastric cancer
    Maruta, Fukuto
    Ishizone, Satoshi
    Hiraguri, Manabu
    Fujimori, Yoshiro
    Shimizu, Fumiaki
    Kumeda, Shigeyoshi
    Miyagawa, Shinichi
    MEDICAL ONCOLOGY, 2007, 24 (01) : 71 - 75
  • [32] A clinical study of docetaxel with or without 5′DFUR as a second-line chemotherapy for advanced gastric cancer
    Fukuto Maruta
    Satoshi Ishizone
    Manabu Hiraguri
    Yoshiro Fujimori
    Fumiaki Shimizu
    Shigeyoshi Kumeda
    Shinichi Miyagawa
    Medical Oncology, 2007, 24 : 71 - 75
  • [33] Irinotecan - Clinical progress in the second-line therapy of advanced colorectal cancer
    Bokemeyer, C
    ONKOLOGIE, 2000, 23 : 28 - 31
  • [34] Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - NO
    Sorensen, Per Soelberg
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (10) : 1260 - 1263
  • [35] Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis
    Wahlin, Staffan
    Efe, Cumali
    JOURNAL OF HEPATOLOGY, 2021, 74 (03) : 753 - 755
  • [36] A multicenter, open, randomized, phase II study to investigate the sequential administration of docetaxel and intermittent erlotinib versus erlotinib as a second-line therapy for advanced non-small cell lung cancer (NSCLC)
    Aparisi, F.
    Garcia Sanchez, J.
    Sanchez-Hernandez, A.
    Giner, V.
    Munoz-Langa, J.
    Esquerdo, G.
    Lopez Jimenez, A.
    Garde, J.
    Juan Vidal, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer
    Lee, Jeung Eun
    Lee, Hee Seung
    Chung, Moon Jae
    Park, Jeong Youp
    Park, Seung Woo
    Song, Si Young
    Bang, Seungmin
    GUT AND LIVER, 2020, 14 (01) : 135 - 143
  • [38] Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment
    Ramos, M
    González-Ageitos, A
    Amenedo, M
    González-Quintas, A
    Gamazo, JL
    Togores, P
    Losada, G
    Almanza, C
    Romero, C
    Gómez-Martín, C
    JOURNAL OF CHEMOTHERAPY, 2003, 15 (02) : 192 - 197
  • [39] Weekly docetaxel and vinorelbine as second-line therapy in advanced non-small cell lung cancer
    Huber, R
    Schmidt, M
    Borgmeier, A
    LUNG CANCER, 2005, 49 : S248 - S248
  • [40] Helicobacter pylori Eradication Rates and Related Factors by Second-Line Bismuth-Based Quadruple Therapy
    Kim, Sung Eun
    Park, Moo In
    Park, Seun Ja
    Moon, Won
    Lee, Jun Yeob
    Lee, Jin Wook
    Kim, Hae Koo
    Nam, Kyoung Sik
    Nam, Yong Jin
    GASTROENTEROLOGY, 2016, 150 (04) : S881 - S881